Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin fumarate vs sufentanil for postoperative analgesia in kidney transplant patients
ChiCTR2500103170Phase 4Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine and sufentanil in end-stage kidney disease (ESKD), kidney failure and postoperative pain (2 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoints: Pain score and Renal function. Planned start May 2025; status: not yet recruiting.
02
Drugs
oliceridinesufentanil
03
Conditions
end-stage kidney disease (ESKD)kidney failurepostoperative pain
Beyond the preview
Go deeper on ChiCTR2500103170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103170.